Key Stats for CVS Health Stock
- Current Price: $73
- Street Target Price: $96
- Target Price: $128
- Target Return: 63.4%
- Annualized IRR: 10.7%
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
The prevailing market narrative surrounding CVS Health Corporation (CVS) often focuses on regulatory pressures facing Pharmacy Benefit Managers (PBMs) and the ongoing margin recovery in its Aetna Medicare Advantage business.
However, the market is severely underpricing the structural transformation occurring at the retail pharmacy counter.
During the Leerink Global Healthcare Conference in March 2026, Group President Prem Shah detailed a radical shift in how the company generates revenue. In the past, CVS suffered roughly $1 billion in annual reimbursement erosion due to an archaic system of cross-subsidization (losing money on some prescriptions to offset gains on others). To stop this bleed, CVS launched “CostVantage.”
Shah stated verbatim: “We switched the model. We went to payers and worked in a collaborative way to change the model and create a model that’s better for both… We get a fixed margin per script for every script that we dispense.”
This shift replaces a highly volatile, unpredictable pricing system with a simple, transparent formula: cost of goods plus a fixed markup. This removes the guesswork for investors and establishes a solid floor for retail pharmacy margins.
Similarly, on the Caremark (PBM) side, CVS is rolling out “Trucost,” a hyper-transparent, drug-level pricing model that perfectly positions the company for the new wave of PBM legislation slated to take effect in late 2028.
Shah noted that despite having to absorb $500 million in rebate guarantee pressure across 2025 and 2026, Caremark onboarded over $6 billion in net new revenue for the upcoming year while maintaining a >98% retention rate.
See historical and forward estimates for CVS Health stock (It’s free!) >>>
Is CVS Health Undervalued Today?
The market is currently treating CVS as a distressed asset, completely ignoring its massive technological pivot to engage consumers.
The company serves over 90 million people daily, and it is actively leveraging that scale to become the “front door” of healthcare.
CVS officially launched the “Health 100” platform in partnership with Google.
This open-engagement digital ecosystem is designed to coordinate care across a patient’s entire healthcare journey, linking their pharmacy, their PBM, and their health plan into a single, seamless application.
Crucially, this system is not closed to CVS. It allows other pharmacies and PBMs to plug in, positioning CVS as the foundational operating system for consumer healthcare engagement.
By utilizing AI chat features and wearable data integrations, Health 100 actively guides patients to the “next best action” (like scheduling an MTM visit after a hospital discharge or navigating a formulary change).
As Shah highlighted, engaged members are fundamentally lower-cost members, which directly improves outcomes and drives profitability across the Aetna and Caremark segments.
When looking at the company’s massive cash flow and revenue base via the NTM EV/Revenue multiple, CVS clearly deserves a premium for its unmatched vertical integration.
See whether CVS Health is undervalued vs peers (It’s free!) >>>
TIKR Advanced Model Analysis
The TIKR Advanced Model identifies CVS Health as a highly asymmetric turnaround play. The company has successfully stabilized its retail pharmacy reimbursement and is actively recovering margins across its insurance business.
- Current Price: $73
- Street Target Price: $96
- Target Price: $128
- Target Return: 63.4%
- Annualized IRR: 10.7%
Build a 4-year Valuation Model for CVS for yourself (It’s free) >>>
The “Fixed Margin” Lever: The mechanical path to the $127.91 target relies heavily on CVS’s ability to maintain its massive top-line scale while executing its margin recovery playbook. The model’s Mid Case assumes a realistic 4.2% Revenue CAGR over the forecast period. This steady expansion is driven by the $6 billion in net new Caremark wins, the stabilization of the retail pharmacy footprint, and the gradual recovery of the Aetna Medicare Advantage business.
The true fundamental upside, however, rests on the company’s ability to defend its profitability. By utilizing the transparent CostVantage model to secure a fixed margin per script and leveraging the Health 100 platform to lower overall care costs, CVS is forecast to achieve a structurally sound 2.6% Net Income Margin over the forecast period. This combination of massive revenue scale and rebounding profitability easily justifies the modeled 10.7% annualized return, making CVS a highly compelling value opportunity.
Conclusion: The market’s knee-jerk reaction to short-term Medicare Advantage headwinds and PBM headlines is completely ignoring the structural transformation occurring within CVS’s core pharmacy business. By pivoting to the transparent CostVantage reimbursement model, retaining >98% of its PBM clients with Trucost, and launching the foundational Health 100 digital ecosystem, CVS is future-proofing its cash flow. The fundamental upside to a $128 valuation makes CVS an exceptionally strong total-return opportunity.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in CVS Health?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CVS Health, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CVS Health alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Visa Inc. on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
